Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

It’s time to shine for Lucid’s rare disease team

No team members were getting their hands dirty today! Instead, they were treated to car valets and manicures as a thank you for all their hard work delivering a number...

Lucid Group Communications Limited

AstraZeneca AZ

AZ trial adds to pessimism about anti-IL-13 asthma drugs

Firm's IL-13 inhibitor failed to reduce the number of asthma attacks compared to placebo

Roche Basel Switzerland

Tecentriq bladder cancer approval in doubt after trial failure

The PD-L1 inhibitor failed to extend overall survival in a phase III study

- PMLiVE

UCB adds website for its Facebook-based Parkinson’s community

Says the site forms the next chapter for More than Motion

- PMLiVE

IFPMA appoints Fumie Griego as assistant director general

She joins the global pharma association from Merck KGaA

Novartis’ Owen Wallace to lead Fulcrum Therapeutics

The US biotech has also appointed Sanofi's Amit Hasija

- PMLiVE

Gottlieb heading to FDA after clearing Senate vote

Trump’s favoured candidate received bipartisan support despite criticism

- PMLiVE

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

Lucid Group Communications Limited

- PMLiVE

When science is not enough

Mundipharma’s Will Dunlop on a new framework to guide development programmes to a better destination

- PMLiVE

Kymab appoints its first chief medical officer

Dr Sonia Quaratino joins the firm from Novartis

- PMLiVE

Pfizer launches antibiotic resistance surveillance website

Designed for healthcare professional use ATLAS will cover 60 countries

- PMLiVE

Just 20% of people living with hep C are aware of their status

WHO's hepatitis report reveals global impact of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links